Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Ogata, Shohei ^a   Shimizu, Chisato ^a   Franco, Alessandra ^a   Touma, Ranim ^a   Kanegaye, John T ^a,b   Choudhury, Biswa P ^c   Naidu, Natasha N ^c   Kanda, Yutaka ^d   Hoang, Long T ^e   Hibberd, Martin L ^e   Tremoulet, Adriana H ^a,b   Varki, Ajit ^c   Burns, Jane C ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

^e GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA GALACTOSIDE A2 6 SIALYLTRANSFERASE I; IMMUNOGLOBULIN G; SIALYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CELL LYSATE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIALYLATION; TREATMENT FAILURE; TREATMENT RESPONSE;

B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL LINE; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUCOSE; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; N-ACETYLNEURAMINIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SIALYLTRANSFERASES; SOLUBILITY; TREATMENT OUTCOME;

EID: 84891921496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081448     Document Type: Article

References (74)

1. Burns JC, Glodé MP (2004) Kawasaki syndrome. Lancet 364:533-544. doi:10.1016/S0140-6736 (04) 16814-1. PubMed: 15302199. (Pubitemid 39070416)
2. Kato H, Sugimura T, Akagi T, Sato N, Hashino K et al. (1996) Longterm consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 94:1379-1385. doi:10.1161/01. CIR. 94.6.1379. PubMed: 8822996. (Pubitemid 26307269)
3. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J et al. (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633-1639. doi:10.1056/NEJM199106063242305. PubMed: 1709446.
4. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E et al. (2008) Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 153:117-121. doi:10.1016/j.jpeds.2007.12.021. PubMed: 18571548.
5. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L et al. (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27:233-245. doi:10.1007/s10875-007-9088-9. PubMed: 17351760. (Pubitemid 46790823)
6. Prins C, Gelfand EW, French LE (2007) Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 87:206-218. PubMed: 17533485. (Pubitemid 47226887)
7. Bussel JB (2002) Another interaction of the FcR system with IVIG. Thromb Haemost 88:890-891. PubMed: 12529734. (Pubitemid 36018771)
8. Crow AR, Song S, Siragam V, Lazarus AH (2006) Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47:710-713. doi:10.1002/pbc. 20980. PubMed: 16933274. (Pubitemid 44360037)
9. Burton DR, Dwek RA (2006) Immunology. Sugar determines antibody activity. Science 313:627-628. doi:10.1126/science.1131712. PubMed: 16888131. (Pubitemid 44201132)
10. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA et al. (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1:237-243. doi:10.1038/nm0395-237. PubMed: 7585040.
11. Selman MH, Niks EH, Titulaer MJ, Verschuuren JJ, Wuhrer M et al. (2011) IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 10:143-152. doi: 10.1021/pr1004373. PubMed: 20672848.
12. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673. doi:10.1126/science.1129594. PubMed: 16888140. (Pubitemid 44201145)
13. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC et al. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373-376. doi:10.1126/science. 1154315. PubMed: 18420934. (Pubitemid 351555659)
14. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 105:19571-19578. doi:10.1073/pnas. 0810163105. PubMed: 19036920.
15. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T (H) 2 pathway. Nature 475:110-113. doi:10.1038/nature10134. PubMed: 21685887.
16. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV (2013) General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A 110:9868-9872. doi:10.1073/pnas. 1307864110. PubMed: 23697368.
17. Yabe R, Tateno H, Hirabayashi J (2010) Frontal affinity chromatography analysis of constructs of DC-SIGN, DC-SIGNR and LSECtin extend evidence for affinity to agalactosylated N-glycans. FEBS J 277:4010-4026. doi:10.1111/j.1742-4658.2010.07792.x. PubMed: 20840590.
18. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN (2013) Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 425:1253-1258. doi:10.1016/j.jmb. 2013.02.006. PubMed: 23416198.
19. Kobata A (2008) The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochim Biophys Acta 1780:472-478. doi:10.1016/j.bbagen. 2007.06.012. PubMed: 17659840. (Pubitemid 351381239)
20. Jones MB, Nasirikenari M, Lugade AA, Thanavala Y, Lau JT (2012) Anti-inflammatory IgG production requires functional P1 promoter in beta-galactoside alpha2, 6-sialyltransferase 1 (ST6Gal-1). Gene - Journal of Biological Chemistry 287:15365-15370. doi:10.1074/jbc. M112.345710.
21. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R et al. (2009) A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9:4143-4153. doi:10.1002/pmic.200800931. PubMed: 19688751.
22. Takahashi N, Ishii I, Ishihara H, Mori M, Tejima S et al. (1987) Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry 26:1137-1144. doi:10.1021/bi00378a023. PubMed: 3567160. (Pubitemid 17030203)
23. Barb AW, Brady EK, Prestegard JH (2009) Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 48:9705-9707. doi: 10.1021/bi901430h. PubMed: 19772356.
24. Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC et al. (2011) ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. J Biol Chem 286:39654-39662. doi: 10.1074/jbc. M111.276063. PubMed: 21930713.
25. Jones MB, Nasirikenari M, Feng L, Migliore MT, Choi KS et al. (2010) Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis. J Biol Chem 285:25009-25017. doi:10.1074/jbc. M110.104406. PubMed: 20529847.
26. Hanasaki K, Varki A, Powell LD (1995) CD22-mediated cell adhesion to cytokine-activated human endothelial cells. Positive and negative regulation by alpha 2-6-sialylation of cellular glycoproteins. The Journal of biological chemistry 270:7533-7542
27. Hanasaki K, Powell LD, Varki A (1995) Binding of human plasma sialoglycoproteins by the B cell-specific lectin CD22. Selective recognition of immunoglobulin M and haptoglobin. J Biol Chem 270:7543-7550. doi:10.1074/jbc.270.13.7543. PubMed: 7706301.
28. Hanasaki K, Varki A, Stamenkovic I, Bevilacqua MP (1994) Cytokineinduced beta-galactoside alpha-2, 6-sialyltransferase in human endothelial cells mediates alpha 2, 6-sialylation of adhesion molecules and CD22 ligands. J Biol Chem 269:10637-10643. PubMed: 8144653.
29. Nasirikenari M, Segal BH, Ostberg JR, Urbasic A, Lau JT (2006) Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. Blood 108:3397-3405. doi:10.1182/blood-2006-04-014779. PubMed: 16849643.
30. Nasirikenari M, Chandrasekaran EV, Matta KL, Segal BH, Bogner PN et al. (2010) Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation. J Leukoc Biol 87:457-466. doi: 10.1189/jlb.1108704. PubMed: 20007243.
31. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY et al. (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110:2747-2771. doi:10.1161/01. CIR. 0000145143.19711.78. PubMed: 15505111. (Pubitemid 39453026)
32. Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y et al. (2009) Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Pediatr Res 66:577-584. doi:10.1203/PDR.0b013e3181baa3c2. PubMed: 19680167.
33. Lo NW, Lau JT (1996) Transcription of the beta-galactoside alpha 2, 6-sialyltransferase gene in B lymphocytes is directed by a separate and distinct promoter. Glycobiology 6:271-279. doi:10.1093/glycob/6.3.271. PubMed: 8724135.
34. Lo NW, Lau JT (1999) Transcription of the beta-galactoside alpha2, 6-sialyltransferase gene (SIAT1) in B-lymphocytes: cell type-specific expression correlates with presence of the divergent 5'-untranslated sequence. Glycobiology 9:907-914. doi:10.1093/glycob/9.9.907. PubMed: 10460832. (Pubitemid 29435864)
35. Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO et al. (2011) Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 4:16-25. doi:10.1161/CIRCIMAGING.110.955351. PubMed: 21127203.
36. Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW et al. (2007) Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 8:R261. doi:10.1186/gb-2007-8-12-r261. PubMed: 18067656.
37. Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30 Suppl 1:S9-14. doi:10.1007/s10875-010-9405-6. PubMed: 20480216.
38. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469-16477. doi:10.1074/jbc. M100350200. PubMed: 11297532.
39. Stanley P, Schachter H, Taniguchi N (2009) N-Glycans. In: A VarkiRD CummingsJD EskoHH FreezeP Stanley. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY).
40. Scanlan CN, Burton DR, Dwek RA (2008) Making autoantibodies safe. Proc Natl Acad Sci U S A 105:4081-4082. doi:10.1073/pnas. 0801192105. PubMed: 18344326. (Pubitemid 351754337)
41. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486. doi:10.1126/science.291.5503.484. PubMed: 11161202. (Pubitemid 32097072)
42. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50. doi:10.1146/annurev. immunol.25.022106.141702. PubMed: 17029568. (Pubitemid 46697901)
43. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M et al. (2007) Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17:104-118. PubMed: 17012310. (Pubitemid 44932818)
44. Nimmerjahn F, Anthony RM, Ravetch JV (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A 104:8433-8437. doi:10.1073/pnas.0702936104. PubMed: 17485663. (Pubitemid 47175505)
45. Varki A (2008) Sialic acids in human health and disease. Trends Mol Med 14:351-360. doi:10.1016/j.molmed.2008.06.002. PubMed: 18606570.
46. Varki A, Schauer R (2009) Sialic Acids. In: A VarkiRD CummingsJD EskoHH FreezeP Stanley. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY).
47. Blank M, Shoenfeld Y (2010) Sialic acid-IVIg targeting CD22. Blood 116:1630-1632. doi:10.1182/blood-2010-06-289892. PubMed: 20829376.
48. Acharya M, Borland G, Edkins AL, Maclellan LM, Matheson J et al. (2010) CD23/FcepsilonRII: molecular multi-tasking. Clin Exp Immunol 162:12-23. doi:10.1111/j.1365-2249.2010.04210.x. PubMed: 20831712.
49. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R et al. (2005) The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 202:751-760. doi:10.1084/jem.20050811. PubMed: 16172256. (Pubitemid 41345964)
50. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR et al. (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 18:1401-1406. doi:10.1038/nm.2862. PubMed: 22922409.
51. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979-989. doi:10.1016/S0022-2836 (02) 01250-0. PubMed: 12527303. (Pubitemid 36263407)
52. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H et al. (2007) Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368:767-779. doi: 10.1016/j.jmb.2007.02.034. PubMed: 17368483. (Pubitemid 46527615)
53. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem 278:3466-3473. PubMed: 12427744. (Pubitemid 36801263)
54. Spiegelberg HL, Abel CA, Fishkin BG, Grey HM (1970) Localization of the carbohydrate within the variable region of light and heavy chains of human gamma g myeloma proteins. Biochemistry 9:4217-4223. doi: 10.1021/bi00823a025. PubMed: 5458650.
55. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F (2008) Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 8:2858-2871. doi: 10.1002/pmic.200700968. PubMed: 18655055.
56. Holland M, Yagi H, Takahashi N, Kato K, Savage CO et al. (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 1760:669-677. doi:10.1016/j.bbagen. 2005.11.021. PubMed: 16413679.
57. Anumula KR (2012) Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. J Immunol Methods 382:167-176. doi:10.1016/j.jim.2012.05.022. PubMed: 22683540.
58. Puciæ M, Knezeviæ A, Vidic J, Adamczyk B, Novokmet M et al. (2011) High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10:010090-21653738.
59. Collins BE, Smith BA, Bengtson P, Paulson JC (2006) Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 7:199-206. doi:10.1038/ni1283. PubMed: 16369536. (Pubitemid 43135886)
60. Ghosh S, Bandulet C, Nitschke L (2006) Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2, 6-linked sialic acids. Int Immunol 18:603-611. doi:10.1093/intimm/dxh402. PubMed: 16497829.
61. Haas KM, Sen S, Sanford IG, Miller AS, Poe JC et al. (2006) CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 177:3063-3073. PubMed: 16920943. (Pubitemid 44277823)
62. Hennet T, Chui D, Paulson JC, Marth JD (1998) Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A 95:4504-4509. doi:10.1073/pnas.95.8.4504. PubMed: 9539767. (Pubitemid 128620781)
63. Lauc G, Huffman JE, Puèiæ M, Zgaga L, Adamczyk B et al. (2013) Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 9:e1003225. PubMed: 23382691.
64. Wang XC, Smith TJ, Lau JT (1990) Transcriptional regulation of the liver beta-galactoside alpha 2, 6-sialyltransferase by glucocorticoids. J Biol Chem 265:17849-17853. PubMed: 2211665.
65. Svensson EC, Conley PB, Paulson JC (1992) Regulated expression of alpha 2, 6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP. J Biol Chem 267:3466-3472. PubMed: 1737800.
66. Wang X, Vertino A, Eddy RL, Byers MG, Jani-Sait SN et al. (1993) Chromosome mapping and organization of the human beta-galactoside alpha 2, 6-sialyltransferase gene. Differential and cell-type specific usage of upstream exon sequences in B-lymphoblastoid cells. J Biol Chem 268:4355-4361. PubMed: 7786324. (Pubitemid 23072979)
67. Weinstein J, Lee EU, McEntee K, Lai PH, Paulson JC (1987) Primary structure of beta-galactoside alpha 2, 6-sialyltransferase. Conversion of membrane-bound enzyme to soluble forms by cleavage of the NH2-terminal signal anchor. J Biol Chem 262:17735-17743. PubMed: 3121604. (Pubitemid 18032263)
68. Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, et al. (2008) Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. The Journal of allergy and clinical immunology 122:1008-1013 e1008
69. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K et al. (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606-2612. doi:10.1161/CIRCULATIONAHA.105. 592865. PubMed: 16735679. (Pubitemid 43948009)
70. Saade S, Cazier JB, Ghassibe-Sabbagh M, Youhanna S, Badro DA et al. (2011) Large scale association analysis identifies three susceptibility loci for coronary artery disease. PLOS ONE 6:e29427. doi:10.1371/journal.pone.0029427. PubMed: 22216278.
71. Lindhout E, Lakeman A, Mevissen ML, de Groot C (1994) Functionally active Epstein-Barr virus-transformed follicular dendritic cell-like cell lines. J Exp Med 179:1173-1184. doi:10.1084/jem.179.4.1173. PubMed: 8145036. (Pubitemid 24091776)
72. Li CR, Yang XQ, Shen J, Li YB, Jiang LP (1990) Immunoglobulin G subclasses in serum and circulating immune complexes in patients with Kawasaki syndrome. Pediatr Infect Dis J 9:544-547. doi: 10.1097/00006454-199008000-00003. PubMed: 2235169. (Pubitemid 20260475)
73. Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, et al. (2012) Calcineurin inhibitor treatment of intravenous immunoglobulinresistant Kawasaki disease. The Journal of pediatrics 161:506-512 e501
74. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T et al. (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379:1613-1620. doi:10.1016/S0140- 6736 (11) 61930-2. PubMed: 22405251.